An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

Inclusion Criteria: * Participant meets the Diagnostic and Statistical Manual of Mental Disorders (Edition 4) criteria for schizophrenia * Participant is previously non-acute (on the same antipsychotic medication used for the treatment of schizophrenia and Clinical Global Impression-Severity \[CGI-S\] change less than or equal to 1 in the past 4 weeks before enrollment) and has been given an adequate dose of an appropriate oral antipsychotic for an adequate period of time prior to enrollment, but previous treatment is considered unsuccessful due to one or more of the following reasons: lack of effectiveness, lack of tolerability or safety, lack of compliance and/or other reasons to switch to another antipsychotic medication * Participant is healthy on the basis of a physical examination and vital signs at screening * Female participants must be postmenopausal for at least 1 year, surgically sterile, abstinent, or, if sexually active, agree to practice an effective method of birth control before entry and throughout the study * Participants must be willing and able to fill out self-administered questionnaires Exclusion Criteria: * Participants on clozapine, any conventional depot neuroleptic or risperidone long-acting injection during the last 3 months * Participants with serious unstable medical condition, including known clinically relevant laboratory abnormalities * Participants with history or current symptoms of tardive dyskinesia (twitching or jerking movements that y…